Cargando…

Targeting Mitochondria in Diabetes

Type 2 diabetes (T2D), one of the most prevalent noncommunicable diseases, is often preceded by insulin resistance (IR), which underlies the inability of tissues to respond to insulin and leads to disturbed metabolic homeostasis. Mitochondria, as a central player in the cellular energy metabolism, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Krako Jakovljevic, Nina, Pavlovic, Kasja, Jotic, Aleksandra, Lalic, Katarina, Stoiljkovic, Milica, Lukic, Ljiljana, Milicic, Tanja, Macesic, Marija, Stanarcic Gajovic, Jelena, Lalic, Nebojsa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233932/
https://www.ncbi.nlm.nih.gov/pubmed/34205752
http://dx.doi.org/10.3390/ijms22126642
_version_ 1783713965172326400
author Krako Jakovljevic, Nina
Pavlovic, Kasja
Jotic, Aleksandra
Lalic, Katarina
Stoiljkovic, Milica
Lukic, Ljiljana
Milicic, Tanja
Macesic, Marija
Stanarcic Gajovic, Jelena
Lalic, Nebojsa M.
author_facet Krako Jakovljevic, Nina
Pavlovic, Kasja
Jotic, Aleksandra
Lalic, Katarina
Stoiljkovic, Milica
Lukic, Ljiljana
Milicic, Tanja
Macesic, Marija
Stanarcic Gajovic, Jelena
Lalic, Nebojsa M.
author_sort Krako Jakovljevic, Nina
collection PubMed
description Type 2 diabetes (T2D), one of the most prevalent noncommunicable diseases, is often preceded by insulin resistance (IR), which underlies the inability of tissues to respond to insulin and leads to disturbed metabolic homeostasis. Mitochondria, as a central player in the cellular energy metabolism, are involved in the mechanisms of IR and T2D. Mitochondrial function is affected by insulin resistance in different tissues, among which skeletal muscle and liver have the highest impact on whole-body glucose homeostasis. This review focuses on human studies that assess mitochondrial function in liver, muscle and blood cells in the context of T2D. Furthermore, different interventions targeting mitochondria in IR and T2D are listed, with a selection of studies using respirometry as a measure of mitochondrial function, for better data comparison. Altogether, mitochondrial respiratory capacity appears to be a metabolic indicator since it decreases as the disease progresses but increases after lifestyle (exercise) and pharmacological interventions, together with the improvement in metabolic health. Finally, novel therapeutics developed to target mitochondria have potential for a more integrative therapeutic approach, treating both causative and secondary defects of diabetes.
format Online
Article
Text
id pubmed-8233932
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82339322021-06-27 Targeting Mitochondria in Diabetes Krako Jakovljevic, Nina Pavlovic, Kasja Jotic, Aleksandra Lalic, Katarina Stoiljkovic, Milica Lukic, Ljiljana Milicic, Tanja Macesic, Marija Stanarcic Gajovic, Jelena Lalic, Nebojsa M. Int J Mol Sci Review Type 2 diabetes (T2D), one of the most prevalent noncommunicable diseases, is often preceded by insulin resistance (IR), which underlies the inability of tissues to respond to insulin and leads to disturbed metabolic homeostasis. Mitochondria, as a central player in the cellular energy metabolism, are involved in the mechanisms of IR and T2D. Mitochondrial function is affected by insulin resistance in different tissues, among which skeletal muscle and liver have the highest impact on whole-body glucose homeostasis. This review focuses on human studies that assess mitochondrial function in liver, muscle and blood cells in the context of T2D. Furthermore, different interventions targeting mitochondria in IR and T2D are listed, with a selection of studies using respirometry as a measure of mitochondrial function, for better data comparison. Altogether, mitochondrial respiratory capacity appears to be a metabolic indicator since it decreases as the disease progresses but increases after lifestyle (exercise) and pharmacological interventions, together with the improvement in metabolic health. Finally, novel therapeutics developed to target mitochondria have potential for a more integrative therapeutic approach, treating both causative and secondary defects of diabetes. MDPI 2021-06-21 /pmc/articles/PMC8233932/ /pubmed/34205752 http://dx.doi.org/10.3390/ijms22126642 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Krako Jakovljevic, Nina
Pavlovic, Kasja
Jotic, Aleksandra
Lalic, Katarina
Stoiljkovic, Milica
Lukic, Ljiljana
Milicic, Tanja
Macesic, Marija
Stanarcic Gajovic, Jelena
Lalic, Nebojsa M.
Targeting Mitochondria in Diabetes
title Targeting Mitochondria in Diabetes
title_full Targeting Mitochondria in Diabetes
title_fullStr Targeting Mitochondria in Diabetes
title_full_unstemmed Targeting Mitochondria in Diabetes
title_short Targeting Mitochondria in Diabetes
title_sort targeting mitochondria in diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233932/
https://www.ncbi.nlm.nih.gov/pubmed/34205752
http://dx.doi.org/10.3390/ijms22126642
work_keys_str_mv AT krakojakovljevicnina targetingmitochondriaindiabetes
AT pavlovickasja targetingmitochondriaindiabetes
AT joticaleksandra targetingmitochondriaindiabetes
AT lalickatarina targetingmitochondriaindiabetes
AT stoiljkovicmilica targetingmitochondriaindiabetes
AT lukicljiljana targetingmitochondriaindiabetes
AT milicictanja targetingmitochondriaindiabetes
AT macesicmarija targetingmitochondriaindiabetes
AT stanarcicgajovicjelena targetingmitochondriaindiabetes
AT lalicnebojsam targetingmitochondriaindiabetes